Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

BMC Cancer

Table 7 Risk of SPM after lung HGNEC, stratified by latency

	6–11 months			95% CI	Excess risk	12–59 months			95% CI	Excess risk	60–119 months				Excess risk	120+ months				Excess risk
	O	E	O/E	95% CI	Excess risk	O	E	O/E	95% CI	Excess risk	O	E	O/E	95% CI	Excess risk	O	E	O/E	95% CI	Excess risk
All Sites	174	236.63	0.74	0.63–0.85	−40.5	679	458.53	1.48	1.37–1.6	73.86	380	152.97	2.48	2.24–2.75	241.94	128	39.35	3.25	2.71–3.87	389.58
All Solid Tumours	162	211.36	0.77	0.65–0.89	−31.91	603	408.91	1.47	1.36–1.6	65.02	356	135.52	2.63	2.36–2.91	234.95	120	34.63	3.47	2.87–4.14	375.2
Oral Cavity and Pharynx	9	5.45	1.65	0.75–3.13	2.29	14	10.3	1.36	0.74–2.28	1.24	5	3.42	1.46	0.47–3.41	1.68	2	0.88	2.26	0.27–8.16	4.9
Digestive System	53	43.96	1.21	0.9–1.58	5.84	105	85.1	1.23	1.01–1.49	6.67	51	28.64	1.78	1.33–2.34	23.82	18	7.46	2.41	1.43–3.81	46.33
Respiratory System	34	38.64	0.88	0.61–1.23	−3	317	74.79	4.24	3.78–4.73	81.14	222	25.03	8.87	7.74–10.12	209.9	77	6.52	11.81	9.32–14.76	309.74
Breast	15	30.34	0.49	0.28–0.82	−9.92	39	64.32	0.61	0.43–0.83	−8.48	26	21.86	1.19	0.78–1.74	4.41	6	5.66	1.06	0.39–2.31	1.51
Female Genital System	2	11.64	0.17	0.02–0.62	−6.23	12	24.82	0.48	0.25–0.84	−4.29	5	8.47	0.59	0.19–1.38	−3.7	1	2.17	0.46	0.01–2.57	−5.14
Male Genital System	10	42.93	0.23	0.11–0.43	−21.29	30	74.99	0.4	0.27–0.57	−15.07	12	21.95	0.55	0.28–0.96	−10.6	7	4.97	1.41	0.57–2.9	8.9
Urinary System	28	20.22	1.39	0.92–2	5.03	62	38.71	1.6	1.23–2.05	7.8	23	13.5	1.7	1.08–2.56	10.12	4	3.6	1.11	0.3–2.85	1.76
All Lymphatic and Hematopoietic Diseases	7	19.72	0.35	0.14–0.73	−8.23	61	38.79	1.57	1.2–2.02	7.44	21	13.66	1.54	0.95–2.35	7.82	6	3.7	1.62	0.6–3.53	10.12

ISSN: 1471-2407